The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1475
August 17, 2015
View Complete Issue         Table of Contents 2019 
Brexpiprazole (Rexulti) for Schizophrenia and Depression
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Brexpiprazole (Rexulti) for Schizophrenia and Depression
August 17, 2015 (Issue: 1475)
The FDA has approved the oral, once-daily, second-generation antipsychotic brexpiprazole (Rexulti – Otsuka/Lundbeck) for treatment of schizophrenia and as an adjunct to antidepressants for treatment of major depressive disorder (MDD)....more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Brexpiprazole (Rexulti) for Schizophrenia and Depression
Article code: 1475c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.